Dr. Soliman Abdel Kader Fakeeh Hospital Co. (Fakeeh Care) reported a slight rise in 2025 net profit to SAR 290.2 million, compared to SAR 287.6 million in 2024.
| Item | 2024 | 2025 | Change |
|---|---|---|---|
| Revenues | 2,790.88 | 3,090.25 | 10.7 % |
| Gross Income | 699.04 | 703.89 | 0.7 % |
| Operating Income | 359.06 | 308.00 | (14.2 %) |
| Net Income | 287.55 | 290.18 | 0.9 % |
| Average Shares | 232.00 | 232.00 | - |
| Earnings Per Share before unusual items (Riyals) | 1.24 | 1.25 | 0.9 % |
| EPS (Riyal) | 1.24 | 1.25 | 0.9 % |
Fakeeh Care said the annual profit growth was driven by an 11% year-on-year (YoY) rise in the group’s revenue to SAR 3.09 billion. This was supported by an 8% increase in the number of patients to 1.9 million. Demand remained strong across the group’s facilities, especially at Riyadh and Madinah hospitals, which are still ramping up operations by expanding specialties and services.
Growth was also aided by higher operating capacity. The number of operational beds increased to 544 in Q4 2025, compared to 457 in Q4 2024, due to expanded capacity at the Riyadh hospital and the gradual opening of the Madinah hospital.
Revenue also benefited from a better case mix, with more complex and higher-value treatments.
The net profit attributable to shareholders remained solid, spurred by strong performance from mature operations and improved contribution from the Riyadh hospital as it moves toward breakeven. Excluding the impact of the Madinah hospital, net profit would have increased 14% year-on-year to SAR 332 million.
EBITDA declined to SAR 496 million in 2025, from SAR 522 million a year earlier.
EBITDA, excluding the impact of the Madinah hospital, rose to SAR 560 million, compared to SAR 528 million last year.
| Item | Q4 2024 | Q4 2025 | Change |
|---|---|---|---|
| Revenues | 742.68 | 799.13 | 7.6 % |
| Gross Income | 164.76 | 169.89 | 3.1 % |
| Operating Income | 72.23 | 75.28 | 4.2 % |
| Net Income | 73.77 | 64.21 | (13.0 %) |
| Average Shares | 232.00 | 232.00 | - |
| Earnings Per Share before unusual items (Riyal) | 0.32 | 0.28 | (13.0 %) |
| EPS (Riyal) | 0.32 | 0.28 | (13.0 %) |
| Item | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Revenues | 778.26 | 799.13 | 2.7 % |
| Gross Income | 177.25 | 169.89 | (4.1 %) |
| Operating Income | 70.26 | 75.28 | 7.1 % |
| Net Income | 71.64 | 64.21 | (10.4 %) |
| Average Shares | 232.00 | 232.00 | - |
| Earnings Per Share before unusual items (Riyal) | 0.31 | 0.28 | (10.4 %) |
| EPS (Riyal) | 0.31 | 0.28 | (10.4 %) |
In Q4 2025, the healthcare services provider recorded net earnings of SAR 64.2 million, down 13% from SAR 73.7 million in the year-earlier period.
Compared to Q3 2025, Fakeeh Care’s net earnings declined by 10.4% from SAR 71.6 million.
Shareholders’ equity, after minority interest, came in at SAR 3.17 billion as of Dec. 31, 2025, up from SAR 2.94 billion a year earlier.
Attached Documents
| Company | Estimated | Actual | Change |
|---|---|---|---|
| DALLAH HEALTH | 131.87 | 116.55 | |
| FAKEEH CARE | 57.20 | 64.21 | |
| AVALON PHARMA | 45.97 | 44.52 | |
| YCC | 30.40 | 24.57 | |
| SABIC | (17434.05) | (20940.00) | |
| SACO | 9.80 | (3.93) | |
| SAUDI ENERGY | (3760.00) | (894.00) | |
| TAIBA | 87.80 | 66.00 | |
| TADAWUL GROUP | 65.87 | 96.19 | |
| AMAK | 103.50 | 70.94 |
| Company | Estimated | Actual | Change |
|---|---|---|---|
| DALLAH HEALTH | 131.87 | 145.55 | |
| FAKEEH CARE | 57.20 | 64.21 | |
| AVALON PHARMA | 45.97 | 44.52 | |
| YCC | 30.40 | 24.57 | |
| SABIC | (17434.05) | (5740.00) | |
| SACO | 9.80 | 12.23 | |
| SAUDI ENERGY | (3760.00) | (894.00) | |
| TAIBA | 87.80 | 66.00 | |
| TADAWUL GROUP | 65.87 | 96.19 | |
| AMAK | 103.50 | 70.94 |
Be the first to comment
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website

Comments Analysis: